| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
NDH-1[1]
NDH-1 inhibitor-1 targets NDH-1 (NADH dehydrogenase-1), a key enzyme in the mitochondrial electron transport chain. It has pI50 values of <4, 5.40, and 6.15 µM for bovine SMP (submitochondrial particles), potato SMP, and E. coli, respectively. By inhibiting NDH-1, it modulates mitochondrial function. |
|---|---|
| ln Vitro |
In vitro, NDH-1 inhibitor-1 is a potent NDH-1 inhibitor with pI50 values of <4, 5.40, and 6.15 µM for bovine SMP, potato SMP, and E. coli. It shows species-specific inhibition potency. It is used to study mitochondrial function and energy metabolism.
|
| ln Vivo |
In vivo, NDH-1 inhibitor-1 has potential therapeutic implications in diseases related to mitochondrial dysfunction, such as neurodegenerative disorders and metabolic diseases. However, detailed in vivo efficacy and safety data are limited. Further animal studies are needed.
|
| Enzyme Assay |
Cell-free enzyme assays for NDH-1 inhibitor-1: NDH-1 activity is measured using NADH as substrate and monitoring the decrease in absorbance at 340 nm. Submitochondrial particles (SMP) from bovine, potato, or E. coli are incubated with varying concentrations of the compound (0.1-100 µM). pI50 values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for NDH-1 inhibitor-1: cells are cultured and treated with NDH-1 inhibitor-1 at concentrations of 0.1-100 µM for 24-72 hours. Mitochondrial function is assessed by measuring oxygen consumption rate (OCR) and extracellular acidification rate (ECAR). Cell viability is measured by MTT assay. Reactive oxygen species (ROS) production is measured using fluorescent probes.
|
| Animal Protocol |
In vivo animal studies for NDH-1 inhibitor-1: animal models of mitochondrial dysfunction (e.g., neurodegenerative disease models) would be used. Animals are administered NDH-1 inhibitor-1 orally or intraperitoneally at doses of 1-10 mg/kg. Mitochondrial function, energy metabolism, and disease progression are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of NDH-1 inhibitor-1: as a small molecule (molecular weight 321.37), it may have moderate oral bioavailability and tissue distribution. It is likely metabolized in the liver and excreted via the kidneys. Detailed PK studies are needed to determine its half-life and tissue penetration.
|
| Toxicity/Toxicokinetics |
Toxicity of NDH-1 inhibitor-1: comprehensive toxicity data are limited. As a mitochondrial inhibitor, it may have dose-dependent toxicity due to effects on cellular energy production. It is for research use only and not approved for clinical use.
|
| References |
[1]. Satoh T, et al. Comparison of the inhibitory action of synthetic capsaicin analogues with various NADH-ubiquinone oxidoreductases. Biochim Biophys Acta. 1996 Jan 11;1273(1):21-30.
|
| Additional Infomation |
NDH-1 inhibitor-1 is a research compound with potential applications in mitochondrial research and diseases related to mitochondrial dysfunction. It is available as a reference standard for pharmacological studies. Its mechanism involves inhibition of NDH-1. No clinical trials or FDA approvals have been reported.
|
| Molecular Formula |
C20H19NO3
|
|---|---|
| Molecular Weight |
321.37
|
| Exact Mass |
321.136
|
| CAS # |
173964-49-3
|
| PubChem CID |
4880007
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.178±0.06 g/cm3(Predicted)
|
| Boiling Point |
564.1±40.0 °C(Predicted)
|
| LogP |
3.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
24
|
| Complexity |
414
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=C2C(C=CC=C2)=CC=C1C(NCC1=CC=C(OC)C(OC)=C1)=O
|
| InChi Key |
UBQYRPXGIQUWQD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H19NO3/c1-23-18-10-7-14(11-19(18)24-2)13-21-20(22)17-9-8-15-5-3-4-6-16(15)12-17/h3-12H,13H2,1-2H3,(H,21,22)
|
| Chemical Name |
N-[(3,4-dimethoxyphenyl)methyl]naphthalene-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (388.96 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1117 mL | 15.5584 mL | 31.1168 mL | |
| 5 mM | 0.6223 mL | 3.1117 mL | 6.2234 mL | |
| 10 mM | 0.3112 mL | 1.5558 mL | 3.1117 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
